Castor Blog

Sword Health treated clinical evidence as a strategy, not a one-time study. Over ten years it used clinical research for three jobs in sequence: to overcome clinician skepticism, to establish digital care as a new standard, and to prove cost-effectiveness for reimbursement. In this session with Castor’s Derk Arts, Sword CMO Fernando Correia explains how the company built a real-world dataset of more than 200,000 low back pain patients on its own systems, ran two randomized trials on Castor comparing digital and in-person care, and designed studies that hold up in the real world. Watch the conversation on demand.

Explore how Castor’s 2025 updates reduce site burden and boost compliance through scalable, flexible DTP workflows.

Hard truths on scaling biotech: data isn’t enough, CEOs matter, and funding follows story—not science.

Poor comprehension of informed consent disrupts trials. Here’s how to fix it—with data, tech, and actual patient understanding.

Adopt AI in clinical research with confidence using a risk-based framework that ensures privacy, security, and regulatory alignment.

What a Museum of Medicine can teach us about trials, trust, and how the public sees (or doesn’t see) biomedical progress.

It’s time to move beyond digital PDFs. Discover how real eConsent can transform trials, reduce dropout, and respect autonomy for all.

How do you decide between building, buying, or partnering? Learn key decision factors and red flags to avoid costly missteps.

High R&D costs aren’t due to a lack of innovation but inefficiencies in trials. Here’s how we can fix the system.